Fang Yang - Profile and Investment Details

Investor Profile

Fang Yang is a Venture Capital, Private Equity Firm based in Shanghai, China with a diverse investment portfolio that includes companies such as LevitasBio, ARMO BioSciences, Mammoth Biosciences, Cue, Hummingbird Bioscience, SentreHEART, GeneWEAVE, Baoyuan Biomedical, Invitae, ReadCoor, Bioheng, IMPACT Therapeutics, BCFoods, AccuraGen Holdings, Genapsys, Terns Pharmaceuticals, Polares MedicalMynosys Cellular Devices, Encodia, Omniome, Apexigen, Everest Medicines, Checkmate Pharmaceuticals, Neurelis, AnHeart Therapeutics, VelosBio, Mindstrong, Sema4, Aadi Bioscience, Equillium, Arcus Biosciences, EpimAb Biotherapeutics, KeChow Pharma, . Over time, Fang Yang has demonstrated experience in supporting a range of businesses across various sectors.

While it is not publicly confirmed whether Fang Yang is currently seeking new investment opportunities, their past investments provide valuable insight into the types of projects and industries that have attracted their attention.

Startups and entrepreneurs operating in sectors related to Health Care, Investment Management, Chemical, Life Science, Artificial Intelligence (AI), Analytics, Manufacturing, Biotechnology, Clinical Trials, Early Stage IT, Health Diagnostics, Innovation Management, Medical, Therapeutics, Media and Entertainment, Machine Learning, Pharmaceuticals may find it worthwhile to explore potential connections with Fang Yang, as their portfolio suggests a familiarity and interest in this area.

Understanding Fang Yang’s investment history can offer useful context for founders considering outreach and help identify whether there is a potential fit based on strategic alignment and market focus.